logo
logo

Trefoil Therapeutics Announces Third Tranche Of $28 Million Series A Financing Based On Achievement Of Clinical Trial Objectives

Dec 01, 2021•almost 4 years ago

Amount Raised

$28 Million

Round Type

series a

San Diego

Description

Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have funded the third tranche of its $28 million Series A financing to support the development of its engineered FGF-1, TTHX1114 products for the regenerative treatment of corneal diseases. This funding allows Trefoil to expand the STORM clinical program and initiate a clinical trial of the topical formulation.

Company Information

Company

Trefoil Therapeutics

Location

San Diego, California, United States

About

Trefoil Therapeutics is a clinical stage biotechnology company focused on leveraging its engineered FGF-1 protein technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders. Trefoil’s lead product candidate is TTHX1114, an engineered form of naturally occurring FGF-1 designed to stimulate corneal endothelial cell proliferation and migration, thereby reversing vision loss caused by CED. The technology underlying Trefoil’s platform was developed by co-founder Michael Blaber, Ph.D., and is licensed from Florida State University. Learn more at www.trefoiltherapeutics.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech